You are viewing: Rest Of Europe Biobanking Market analysis
Part of: Biobanking Market (Global)

The Rest Of Europe Biobanking Market was valued at $250.5 Million in 2025 and projected to reach to $357 Million by 2030, representing a compound annual growth rate of 7.3%. Rest Of Europe's biobanking market is positioned for sustained growth driven by increasing investments in precision medicine infrastructure and regulatory harmonization across member nations.

Rest Of Europe Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Europe Biobanking Market Trends and Insights

  • This 7.3% compound annual growth rate reflects increasing investment in precision medicine infrastructure, regulatory harmonization across European nations, and rising demand for biological specimen repositories.
  • Rest Of Europe is benefiting from collaborative research initiatives and cross-border data sharing frameworks that strengthen biobanking capabilities across the region. The biobanking sector in Rest Of Europe is driven by growing adoption of personalized healthcare, expanding clinical trial activities, and enhanced funding for genomic research programs.
  • Rest Of Europe's biobanks are increasingly integrating advanced digital technologies and standardized protocols to improve specimen quality and accessibility.
  • Between 2025 and 2030, Rest Of Europe is expected to see accelerated development of specialized biobanks focused on rare diseases, cancer research, and infectious disease surveillance, positioning the region as a key player in European biomedical research..

Key Market Statistics

  • CAGR (2025-2030) 7.3% CAGR
  • Market Size, 2025 ~USD 250.5 Million
  • Forecast, 2030 ~USD 357 Million
  • Country Rest Of Europe

Rest Of Europe Biobanking Market Overview

Steady Regional Growth :

Rest Of Europe's biobanking market is valued at USD 250.5 million in 2025, with a projected CAGR of 7.3% through 2030, reaching USD 357.0 million. This growth outpaces many mature European markets due to emerging infrastructure investments and regulatory modernization.

Regulatory Harmonization Benefits :

Increasing alignment with EU biobanking standards and GDPR compliance frameworks is streamlining operations across Rest Of Europe. This harmonization reduces operational complexity and encourages cross-border specimen sharing and collaborative research initiatives.

Precision Medicine Infrastructure Expansion :

Rest Of Europe is witnessing significant investment in precision medicine capabilities, driving demand for advanced biobanking facilities. National genomics initiatives and personalized treatment programs are accelerating the need for sophisticated specimen management systems.

Growing Biological Repository Demand :

Rising demand for biological specimen repositories across academic institutions, hospitals, and private research organizations is fueling market expansion. Increased focus on biomarker discovery and clinical trial support is strengthening biobank utilization rates.

Rest Of Europe Biobanking Market Dynamics

  • The region's emphasis on biological specimen repositories and biomarker research is creating robust demand for advanced biobanking solutions.
  • Healthcare institutions and research organizations are prioritizing specimen quality management and data integration capabilities. The forecast period through 2030 will see accelerated adoption of automated biobanking systems and digital specimen tracking technologies.
  • Collaborative research networks and cross-border specimen sharing agreements will expand market opportunities.
  • Rest Of Europe's commitment to personalized medicine and genomic research will continue supporting steady market expansion at a 7.3% CAGR..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Rest Of Europe's biobanking market is valued at USD 250.5 million in 2025 and will reach USD 357.0 million by 2030, growing at a 7.3% CAGR.
    • Rest Of Europe is experiencing increased investment in precision medicine and genomic research infrastructure, driving biobank modernization and expansion.
    • Regulatory harmonization and cross-border collaboration frameworks in Rest Of Europe are enhancing specimen sharing and research accessibility across the region.
    • Rest Of Europe's biobanks are adopting digital technologies and specialized focus areas including rare diseases and infectious disease surveillance through 2030.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    Rest Of Europe Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    Target Audience

    • Biobanking Service Providers : Biobank operators and specimen management companies need Rest Of Europe market data to identify expansion opportunities, assess competitive positioning, and develop region-specific service offerings aligned with local regulatory requirements.
    • Healthcare & Research Institutions : Hospitals, academic centers, and research organizations require market intelligence to benchmark biobanking capabilities, justify infrastructure investments, and understand regional adoption trends for precision medicine initiatives.
    • Medical Device & Software Vendors : Biobanking technology providers need Rest Of Europe market insights to prioritize product development, identify customer segments, and develop go-to-market strategies for automated systems and digital specimen tracking solutions.
    • Investment & Private Equity Firms : Investors evaluating biobanking sector opportunities in Rest Of Europe require detailed market forecasts, growth drivers, and competitive analysis to assess investment viability and identify acquisition targets.
    • Pharmaceutical & Biotech Companies : Drug developers and biotech firms need Rest Of Europe biobanking market data to evaluate clinical trial support capabilities, specimen sourcing options, and biomarker research infrastructure availability in the region.

    Key Companies in the Rest Of Europe Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations specific to Rest Of Europe (USD 250.5M in 2025, USD 357M by 2030) with detailed CAGR analysis. Make informed investment and expansion decisions based on region-specific growth trajectories and market dynamics.
    • Regulatory & Compliance Insights : Understand EU harmonization impacts and GDPR compliance requirements specific to Rest Of Europe biobanking operations. Identify regulatory opportunities and navigate cross-border specimen sharing frameworks effectively.
    • Competitive Landscape Analysis : Benchmark against regional competitors and identify market gaps in Rest Of Europe's biobanking sector. Develop targeted strategies for market penetration and partnership opportunities within emerging European markets.
    • Infrastructure Investment Trends : Track precision medicine infrastructure investments and facility expansion plans across Rest Of Europe. Identify procurement opportunities and technology adoption patterns driving biobanking modernization.
    • Strategic Growth Opportunities : Discover high-potential segments within Rest Of Europe's biobanking market, including specimen repository services, digital solutions, and research collaboration networks. Align product development with regional demand drivers.

    Frequently asked questions

    What is the current market size of biobanking in Rest Of Europe?

    Rest Of Europe's biobanking market is valued at USD 250.5 million in 2025 and is projected to grow to USD 357.0 million by 2030.

    What is the expected growth rate for Rest Of Europe's biobanking market?

    Rest Of Europe's biobanking market is expected to grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2030.

    What factors are driving biobanking growth in Rest Of Europe?

    Key drivers in Rest Of Europe include increased precision medicine adoption, regulatory harmonization, cross-border research collaboration, and rising investment in genomic research programs.

    How is Rest Of Europe's biobanking market evolving technologically?

    Rest Of Europe's biobanks are integrating advanced digital technologies, standardized protocols, and specialized focus areas such as rare disease and infectious disease surveillance to improve specimen quality and accessibility.

    What role does regulatory framework play in Rest Of Europe's biobanking market?

    Regulatory harmonization across Rest Of Europe is facilitating cross-border specimen sharing, data accessibility, and collaborative research initiatives that strengthen the overall biobanking ecosystem.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status